U
Ulrike Burk
Researcher at University of Freiburg
Publications - 8
Citations - 3883
Ulrike Burk is an academic researcher from University of Freiburg. The author has contributed to research in topics: Epithelial–mesenchymal transition & Cancer cell. The author has an hindex of 7, co-authored 7 publications receiving 3582 citations.
Papers
More filters
Journal ArticleDOI
A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells
Ulrike Burk,Joerg Schubert,Ulrich F. Wellner,Otto Schmalhofer,Elizabeth Vincan,Simone Spaderna,Thomas Brabletz +6 more
TL;DR: Results indicate that ZEB1 triggers an microRNA‐mediated feedforward loop that stabilizes EMT and promotes invasion of cancer cells, and thus explain the strong intratumorous heterogeneity observed in many human cancers.
Journal ArticleDOI
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs
Ulrich F. Wellner,Jörg Schubert,Ulrike Burk,Otto Schmalhofer,Feng Zhu,Annika G Sonntag,Bettina Waldvogel,Corinne Vannier,Douglas S. Darling,Axel zur Hausen,Valerie G. Brunton,Jennifer P. Morton,Owen J. Sansom,Julia Schüler,Marc P. Stemmler,Christoph Herzberger,Ulrich T. Hopt,Tobias Keck,Simone Brabletz,Thomas Brabletz +19 more
TL;DR: It is proposed that ZEB1 links EMT-activation and stemness-maintenance by suppressingstemness-inhibiting microRNAs (miRNAs) and thereby is a promoter of mobile, migrating cancer stem cells.
Journal ArticleDOI
The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.
Simone Brabletz,Karolina Bajdak,Simone Meidhof,Ulrike Burk,Gabriele Niedermann,Elke Firat,Ulrich F. Wellner,Arno Dimmler,Gerhard Faller,Jörg Schubert,Thomas Brabletz +10 more
TL;DR: It is shown that miR‐200 members target Notch pathway components, such as Jagged1 (Jag1) and the mastermind‐like coactivators Maml2 and Maml3, thereby mediating enhanced Notch activation by ZEB1, which explains increased Notch signalling in some types of cancers.
Journal ArticleDOI
ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
Simone Meidhof,Simone Brabletz,Waltraut Lehmann,Bogdan-Tiberius Preca,Kerstin Mock,Manuel Ruh,Julia Schüler,Maria Berthold,Anika Weber,Ulrike Burk,Michael Lübbert,Michael Lübbert,Martin Puhr,Zoran Culig,Ulrich F. Wellner,Tobias Keck,Peter Bronsert,Simon Küsters,Ulrich T. Hopt,Marc P. Stemmler,Thomas Brabletz,Thomas Brabletz +21 more
TL;DR: The data encourage the application of mechanism‐based combinations of selected epigenetic drugs with standard chemotherapy for the rational treatment of aggressive solid tumors, such as pancreatic cancer.
Journal ArticleDOI
The role of proteases in epithelial-to-mesenchymal cell transitions in cancer
TL;DR: This work conceptually connects the scientific areas of “EMT” and “protease” research by describing how several important classes of proteolytic enzymes are regulated by EMT and how they are involved in initiation and execution of the EMT program.